Predict your next investment

Corporate Venture
lillyventures.com

See what CB Insights has to offer

Investments

98

Portfolio Exits

35

Funds

4

About Lilly Ventures

Lilly Ventures is the venture capital arm of pharmaceutical company, Eli Lilly. Lilly Ventures will look at early to expansion stage investments. Lilly Ventures currently has US$200 million under management and specifically targets opportunities in biotechnology; healthcare IT; and medical technology.

Lilly Ventures Headquarter Location

115 W. Washington Street Suite 1680 - South

Indianapolis, Indiana, 46204,

United States

(317) 651-3050

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Lilly Ventures

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Lilly Ventures in 1 Expert Collection, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

Latest Lilly Ventures News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

Jan 11, 2020

BIOCENTURY Print Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more By BioCentury Staff | Jan 11, 2020 | 1:54 AM GMT Wave Life Sciences Ltd. (NASDAQ:WVE) disclosed in an SEC filing that CFO Keith Regnante stepped down to pursue other opportunities. VP and Corporate Controller David Gaiero will serve as interim CFO, principal accounting officer and principal financial officer (see “More Waves to Come” ). Polaris Partners hired former Lilly exec Darren Carroll as partner. He stepped down as SVP, corporate business development of Eli Lilly and Co. (NYSE:LLY) in August after working at the pharma for 22 years, during which he oversaw the $8 billion takeout of Loxo Oncology Inc. last January. Carroll also formed and led Lilly Ventures and Lilly Asia Ventures (see “Lilly to Acquire Loxo” ). Precision oncology company Turning Point Therapeutics Inc. (NASDAQ:TPTX) said co-founder Jean Cui will step down as CSO, effective Jan. 31, due to family reasons. ADC Therapeutics S.A. hired Joseph Camardo as head of medical affairs. He was an executive at Celgene Corp. for 10 years, most recently as SVP of Celgene Global Health, as well as SVP at Wyeth from 1989-2010. Camardo joins as the company is readying its first BLA submission in the wake of Thursday’s positive data for loncastuximab tesirine (ADCT-402) in diffuse large B cell lymphoma (see “ADC’s Loncastuximab Data Could Clear Path for BLA, IPO Filing” ). Neurology company Relmada Therapeutics Inc. (OTCQB:RLMD) said Maged Shenouda will become CFO and step down from the board. He succeeds Charles Ence, who will become chief accounting and compliance officer. Shenouda was CFO and EVP of corporate development at AzurRx BioPharma Inc. (NASDAQ:AZRX). Aravive Inc. (NASDAQ:ARAV) hired Rekha Hemrajani as president and CEO and appointed her to the board. The cancer and fibrosis company’s previous CEO, Jay Shepard, will become chairman. Hemrajani was COO and CFO at Arcus Biosciences Inc. (NYSE:RCUS). Immuno-oncology company Affimed N.V. (NASDAQ:AFMD) hired Andreas Harstrick as CMO, effective March 2020, to succeed Leila Alland. He was CMO at Molecular Partners AG (SIX:MOLN). Impel NeuroPharma Inc., which is developing intranasal therapies for neurological diseases, appointed Adrian Adams as chairman. Adams was CEO at Aralez Pharmaceuticals Inc. and its predecessor Pozen Inc. Viral immuno-oncology company Candel Therapeutics hired Sandra Poole as COO. Poole was COO at LogicBio Therapeutics Inc. (NASDAQ:LOGC) and serves on the boards of Retrophin Inc. (NASDAQ:RTRX), ViaCyte Inc. and Valneva SE (Euronext Paris:VLA; VSE:VLA). Neurology company TauC3 Biologics Ltd. appointed Andrew Heath as non-executive chairman and Shafique Virani as non-executive director. Heath is deputy chairman and senior independent director at Oxford BioMedica plc (LSE:OXB). Virani was CEO-in-residence at BridgeBio Pharma Inc. (NASDAQ:BBIO) and CEO of Navire Pharma Inc. and BridgeBio subsidiary CoA Therapeutics Inc. Glauconix Biosciences Inc. promoted Kim Southern to CEO from COO and appointed her to the board. The ophthalmic specialty pharma research company uses 3D tissue culture systems for drug development. Rare endocrine disease company MBX Biosciences made co-founder and board member Kent Hawryluk president and CEO. Hawryluk co-founded and was CBO at Avidity Biosciences LLC.

Lilly Ventures Investments

98 Investments

Lilly Ventures has made 98 investments. Their latest investment was in Acrivon Therapeutics as part of their Series A on February 2, 2021.

CBI Logo

Lilly Ventures Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

2/12/2021

Series A

Acrivon Therapeutics

$20M

Yes

2

6/6/2018

Series E

Sutro Biopharma

$85.4M

No

Alta Partners, Amgen Ventures, Celgene, Citadel, Eventide Asset Management, M Ventures, Nexthera Capital, Samsara BioCapital, Skyline Ventures, SV Health Investors, Tekla Capital Management, and Vida Ventures

5

6/5/2018

Series C

Nimbus Therapeutics

$65M

No

Atlas Venture, Bill Gates, Lightstone Ventures, Pfizer Venture Investments, Schrodinger, and SR One

5

10/30/2017

Series A

Subscribe to see more

$99M

Subscribe to see more

10

5/22/2017

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

2/12/2021

6/6/2018

6/5/2018

10/30/2017

5/22/2017

Round

Series A

Series E

Series C

Series A

Series B

Company

Acrivon Therapeutics

Sutro Biopharma

Nimbus Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$20M

$85.4M

$65M

$99M

$99M

New?

Yes

No

No

Subscribe to see more

Subscribe to see more

Co-Investors

Alta Partners, Amgen Ventures, Celgene, Citadel, Eventide Asset Management, M Ventures, Nexthera Capital, Samsara BioCapital, Skyline Ventures, SV Health Investors, Tekla Capital Management, and Vida Ventures

Atlas Venture, Bill Gates, Lightstone Ventures, Pfizer Venture Investments, Schrodinger, and SR One

Sources

2

5

5

10

10

Lilly Ventures Portfolio Exits

35 Portfolio Exits

Lilly Ventures has 35 portfolio exits. Their latest portfolio exit was Viracta Therapeutics on November 30, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

11/30/2020

Reverse Merger

1

9/25/2020

Acquired

2

8/21/2020

IPO

$991

2

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

11/30/2020

9/25/2020

8/21/2020

00/00/0000

00/00/0000

Exit

Reverse Merger

Acquired

IPO

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

2

2

10

10

Lilly Ventures Fund History

4 Fund Histories

Lilly Ventures has 4 funds, including Lilly Ventures Fund I LLC.

Closing Date

Fund

Fund Type

Status

Amount

Sources

5/1/2009

Lilly Ventures Fund I LLC

Early-Stage Venture Capital

$200M

1

12/15/2003

Lilly MedTech Venture Fund

Subscribe to see more

$99M

10

12/15/2003

e.Lilly Venture Fund

Subscribe to see more

$99M

10

12/15/2003

Lilly BioVenture Fund

Subscribe to see more

$99M

10

Closing Date

5/1/2009

12/15/2003

12/15/2003

12/15/2003

Fund

Lilly Ventures Fund I LLC

Lilly MedTech Venture Fund

e.Lilly Venture Fund

Lilly BioVenture Fund

Fund Type

Early-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Amount

$200M

$99M

$99M

$99M

Sources

1

10

10

10

Lilly Ventures Team

5 Team Members

Lilly Ventures has 5 team members, including current General Partner, Steve Hall.

Name

Work History

Title

Status

Steve Hall

General Partner

Current

Dominick Colangelo

Managing Director

Former

Ron Laufer

Managing Director

Former

Vanessah Ng

Managing Director

Former

Charles E. Schalliol

BioCrossroads, and Eli Lilly and Company

Managing Director

Former

Name

Steve Hall

Dominick Colangelo

Ron Laufer

Vanessah Ng

Charles E. Schalliol

Work History

BioCrossroads, and Eli Lilly and Company

Title

General Partner

Managing Director

Managing Director

Managing Director

Managing Director

Status

Current

Former

Former

Former

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.